Meeting
2011 ASCO Annual Meeting
The effect of a tamoxifen dose increase from 20 mg to 40 mg in patients with at least one inactive CYP2D6 variant allele and/or concomitant use of a CYP2D6 inhibitor.
Authors
M. E. B. Welzen
Department of Clinical Pharmacy, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
M. E. B. Welzen , V. O. Dezentje , R. H. N. van Schaik , E. P. H. Colbers , H. Guchelaar , J. den Hartigh , D. M. Burger , H. Van Laarhoven
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT01192308
Citation
J Clin Oncol 29: 2011 (suppl; abstr 584)
Abstract #
584
Poster Bd #
7B
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Simplified CYP2D6 metabolizer phenotype categorization of patients treated with tamoxifen: Role for endoxifen level monitoring?
First Author: Clara Inkyung Lee
Poster
2011 ASCO Annual Meeting
Patients' understanding of how genotype variation affects benefits of tamoxifen therapy for breast cancer.
First Author: N. T. Brewer
Poster
2018 ASCO Annual Meeting
A randomized phase II trial evaluating CYP2D6 genotype-guided tamoxifen dosing in hormone receptor-positive metastatic breast cancer: TARGET-1.
First Author: Toshimi Takano
Poster
2018 ASCO Annual Meeting
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
First Author: Gerardus Hussaarts